Trifluralin liposomal formulations active against Leishmania donovani infections.
The purpose of this study was to increase the therapeutic index of the antiparasitic drug, trifluralin (TFL), to allow its parenteral administration without the need of toxic solvents. This was achieved by incorporating TFL in liposomes with high loading capacity. These formulations were stable in freeze-dried form during at least one year and in frozen form during at least three months. Therapeutic activity, assessed on a visceral model of infection, showed that TFL liposomes reduced the number of parasites by up to one third or one half as compared to negative control and to free TFL, respectively.
Carvalheiro
Manuela
M
Unit of New Forms of Bioactive Agents, National Institute of Engineering Technology and Innovation, Lisbon, Portugal.
Jorge
João
J
Eleutério
Carla
C
Pinhal
Ana F
AF
Sousa
Ana C
AC
Morais
José G
JG
Cruz
M Eugénia M
ME